An interview with Dr. Lebovics breaking down the key data presented at EASL 2015.
Topics include;
Ledipasvir/Sofosbuvir
Continued use of ribavirin in DAA therapies? Is ribavirin really necessary?
Daclatasvir, Sofosbuvir, and Ribavirin Combination For HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence
What challenges do you think daclatasvir will face should it be approved for use in the US given the current availability of approved DAAs such as ledipasvir/sofosbuvir?
and more...........
Click here to begin
This blog is supported by Elsevier Multimedia Publishing and the American Journal of Medicine (AJM), and serves as a companion to their comprehensive, online, global educational initiative, the AJM Hepatitis C Resource Center (hepcresource.amjmed.com).
Recent posts
- Dr. E Lebovics: Post-EASL 2015 HCV Interview
- Beneficial Effect of Statins on HCV Infection
- Barriers to Accessing HCV Therapies in the US
- EASL 2015 Hepatitis Research: Dr A. Ploss
- Pooled safety data: ledipasvir/sofosbuvir: HCV-1
- Largest DAA study to date in HCV genotype 4
- Special Interview on HCV: Dr. S. Wiktor of WHO
- New list: free peer-reviewed HCV articles: May 8
- Newly Updated EASL 2015 HCV Guidelines
No comments:
Post a Comment